ribavirin has been researched along with 2'-c-methylcytidine in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Elazar, M; Glenn, JS; Korba, BE; Lui, P; Rossignol, JF | 1 |
| Coelmont, L; Dumont, JM; Kaptein, S; Neyts, J; Paeshuyse, J; Vliegen, I; Vuagniaux, G | 1 |
| Abou-Elkhair, RA; Haikal, AZ; Ibraheem, AM; Moustafa, AH | 1 |
| Atzori, EM; Biava, M; Collu, G; Delogu, I; Desideri, N; Droghini, P; Fioravanti, R; Ibba, C; Loddo, R; Sanna, G | 1 |
| Atzori, EM; Briguglio, I; Carta, A; Collu, G; Corona, P; Delogu, I; Desideri, N; Fermeglia, M; Ibba, R; La Colla, P; Laurini, E; Loddo, R; Piras, S; Pricl, S | 1 |
| Groaz, E; Herdewijn, P; Li, Q; Neyts, J; Rocha-Pereira, J | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bartenschlager, R; Coelmont, L; De Clercq, E; Neyts, J; Paeshuyse, J; Windisch, MP | 1 |
| Bassit, L; Bennett, M; Grier, J; Schinazi, RF | 1 |
| Costa, I; Cunha, R; Dallmeier, K; Jochmans, D; Leyssen, P; Nascimento, MS; Neyts, J; Rocha-Pereira, J | 1 |
| Feigelstock, DA; Mihalik, KB | 1 |
| De Clercq, K; De Vleeschauwer, AR; Goris, N; Kollanur, D; Lefebvre, DJ; Murao, LE; Neyts, J; Osiceanu, AM; Swinnen, J | 1 |
| Pan, Q; Peppelenbosch, MP; Qu, C; Wang, W; Xu, L; Yin, Y | 1 |
13 other study(ies) available for ribavirin and 2'-c-methylcytidine
| Article | Year |
|---|---|
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
Topics: Antiviral Agents; Cell Line; Cytidine; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nitro Compounds; Recombinant Proteins; Replicon; Ribavirin; Thiazoles; Virus Replication | 2008 |
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
Topics: Antiviral Agents; Clinical Trials as Topic; Cyclophilins; Cyclosporine; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Hepacivirus; Hepatitis C; Humans; Replicon; Ribavirin; Viral Nonstructural Proteins | 2009 |
Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.
Topics: Bacteria; Microbial Sensitivity Tests; Nitriles; Viruses | 2014 |
N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents.
Topics: Aniline Compounds; Antiviral Agents; Cell Line; Humans; Pyrazoles; Respiratory Syncytial Viruses; Virus Replication | 2015 |
A combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems.
Topics: Animals; Antiviral Agents; Binding Sites; Bovine Virus Diarrhea-Mucosal Disease; Cattle; Diarrhea Viruses, Bovine Viral; Hydrogen Bonding; Models, Molecular; Polycyclic Aromatic Hydrocarbons; RNA-Dependent RNA Polymerase | 2016 |
Anti-norovirus activity of C7-modified 4-amino-pyrrolo[2,1-f][1,2,4]triazine C-nucleosides.
Topics: Animals; Antiviral Agents; Cell Line; Drug Design; Mice; Norovirus; Nucleosides; Pyrroles; Structure-Activity Relationship; Triazines; Virus Replication | 2020 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine.
Topics: Antiviral Agents; Cell Line, Tumor; Cytidine; Drug Antagonism; Drug Therapy, Combination; Hepacivirus; Humans; Ribavirin; Virus Replication | 2006 |
Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system.
Topics: Antiviral Agents; Cells, Cultured; Computer Simulation; Cytidine; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Hepacivirus; Humans; Interferon alpha-2; Interferon-alpha; Models, Chemical; Monte Carlo Method; Polymerase Chain Reaction; Recombinant Proteins; Replicon; Ribavirin; RNA, Ribosomal; RNA, Viral | 2008 |
Inhibition of norovirus replication by the nucleoside analogue 2'-C-methylcytidine.
Topics: Animals; Antiviral Agents; Cell Line; Cytidine; Drug Resistance, Viral; Mice; Norovirus; Ribavirin; Virus Replication | 2012 |
Sensitivity of a ribavirin resistant mutant of hepatitis C virus to other antiviral drugs.
Topics: Amino Acid Substitution; Antiviral Agents; Cell Line; Cytidine; Drug Resistance, Viral; Fluorouracil; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Microbial Sensitivity Tests; Mutation; Ribavirin; Viral Proteins; Virus Replication | 2013 |
In vitro surrogate models to aid in the development of antivirals for the containment of foot-and-mouth disease outbreaks.
Topics: Animals; Antiviral Agents; Aphthovirus; Benzimidazoles; Cattle; Cell Line; Chlorocebus aethiops; Cytidine; Cytopathogenic Effect, Viral; Drug Discovery; Foot-and-Mouth Disease; Models, Theoretical; Oximes; Ribavirin; RNA, Viral; Sulfonamides; Virus Cultivation; Virus Replication | 2014 |
Nucleoside analogue 2'-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin.
Topics: Antiviral Agents; Cell Line; Cytidine; Hepatitis E virus; Humans; Ribavirin; Virus Replication | 2017 |